Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.66 |
| ▸ | CA2 | P00918 | 10/20 | 0.66 |
| ▸ | CA9 | Q16790 | 9/20 | 0.66 |
| ▸ | CA12 | O43570 | 8/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.66 |
| ▸ | CA4 | P22748 | 4/20 | 0.55 |
| ▸ | CA5A | P35218 | 4/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.55 |
| ▸ | CA3 | P07451 | 3/20 | 0.55 |
| ▸ | CA6 | P23280 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17673 | 0.94 | CA2 (0.61) | CA1CA2CA9CA12CA14 | |
| Hydrochloric Acid SCHEMBL7567770 | 0.91 | CA2 (0.59) | CA1CA2CA9CA12CA14 | |
| SCHEMBL28872378 | 0.86 | CA1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL5559803 | 0.86 | ALDH1A1 (0.64) | CA1CA2CA9CA12CA14 | |
| SCHEMBL11854911 | 0.83 | CA1 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL10451887 | 0.83 | CA1 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL4689723 | 0.82 | CA1 (0.63) | CA1CA2CA9CA12CA14 | |
| SCHEMBL11247993 | 0.82 | HSPB1 (0.59) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12570988 | 0.82 | GAA (0.54) | CA1CA2CA9CA5ACA13 | |
| SCHEMBL6423919 | 0.82 | CA1 (0.67) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BAYER IP GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-20140288118-A1 | N-BIARYLAMIDES | BAYER INTELLECTUAL PROPERTY GMBH | 2014-09-25 | — | — | US | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| CN-103596925-A | Benzocycloheptene acetic acids | HOFFMANN LA ROCHE | 2014-02-19 | — | — | CN | disclosed |
| EP-1483244-B1 | CYCLIC N-SUBSTITUTED ALPHA IMINOCARBOXYLIC ACIDS FOR SELECTIVELY INHIBITING COLLAGENASE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1651645-A1 | N-BIARYLAMIDES | Bayer HealthCare AG (DE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005012299-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1483244-A1 | CYCLIC N-SUBSTITUTED ALPHA IMINOCARBOXYLIC ACIDS FOR SELECTIVELY INHIBITING COLLAGENASE | Aventis Pharma Deutschland GmbH (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-6716853-B2 | DEGENERATIVE JOINT DISORDERS; 2-(4'-ALKYLOXYCARBONYLAMINOBI PHENYL-4-SULFONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXY OR THE 4,5,6,7-TETRAHYDRO-1H-IMIDAZO(4,5-C)PYRIDINE RING; SULFONYLATION OF RING N WITH 4-NITROBIPHENYLSULFONIC ACID | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-06 | — | — | US | disclosed |
| US-20030199543-A1 | Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003074489-A1 | CYCLIC N-SUBSTITUTED ALPHA IMINOCARBOXYLIC ACIDS FOR SELECTIVELY INHIBITING COLLAGENASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-12 | — | — | WO | disclosed |
| US-4695405-A | Process for quenching fluorescence, and new cationic or amphoteric aromatic nitro compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199543-A1 | Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase | MMP1, MMP13, TIMP3 | CA1 125/4885CA2 136/4885CA9 67/4885 |
| US-20180325878-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | CA1 654/4885CA2 1806/4885CA9 3855/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | CA1 508/4885CA2 306/4885CA9 269/4885 |
| US-20140288118-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | CA1 654/4885CA2 1806/4885CA9 3855/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | CA1 654/4885CA2 1806/4885CA9 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.